Wed, Nov 13, 2019 – 3:24 PM A LACK of near-term catalysts and tepid earnings growth – both of which are likely to send stock prices sideways – has led RHB Research Institute to downgrade Catalist-listed Singapore Medical Group (SMG) to “neutral” with a target price of S$0.36. That said, RHB analysts JarickRead More →